How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

165 results for

Bile Binding Resin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

2. Bile Binding Resin

Bile Binding Resin Bile Binding Resin Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Bile Binding Resin Bile Binding Resin Aka: Bile (...) Binding Resin , Bile Acid-Binding Resin , Cholestyramine , Colestipol , Colesevelam , Welchol From Related Chapters II. Effects decreased (15-30%) increased (3-5%) s increased III. Efficacy Lowers cardiovascular mortality by 30% Reduces risk IV. Adverse effects Gastrointestinal Effects Reduce Adverse GI side effects Use moderate doses: 8-10 g per day Increase or supplement with Colesevelam may have less GI intolerance Interferes with fat soluble bsorption Take 2 hours before or 4 hours after Resin

2018 FP Notebook

3. Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer. (PubMed)

Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer. Sevelamer, a non-absorbable amine-based resin used for treatment of hyperphosphataemia, has been demonstrated to have a marked bile acid-binding potential alongside beneficial effects on lipid and glucose metabolism. The aim of this study was to investigate the glucose-lowering effect and mechanism(s) of sevelamer in patients with type 2 diabetes.In this double-blinded randomized controlled trial, we (...) randomized 30 patients with type 2 diabetes to sevelamer (n = 20) or placebo (n = 10). Participants were subjected to standardized 4-hour liquid meal tests at baseline and after 7 days of treatment. The main outcome measure was plasma glucagon-like peptide-1 excursions as measured by area under the curve. In addition, blood was sampled for measurements of glucose, lipids, glucose-dependent insulinotropic polypeptide, C-peptide, glucagon, fibroblast growth factor-19, cholecystokinin and bile acids

Full Text available with Trip Pro

2018 obesity & metabolism

4. Effects of bile-acid-binding resin (colestimide) on blood glucose and visceral fat in Japanese patients with type 2 diabetes mellitus and hypercholesterolemia: an open-label, randomized, case-control, crossover study. (PubMed)

Effects of bile-acid-binding resin (colestimide) on blood glucose and visceral fat in Japanese patients with type 2 diabetes mellitus and hypercholesterolemia: an open-label, randomized, case-control, crossover study. The objective was to examine the effects of colestimide on blood glucose, visceral fat, adipocytokines, and bile acid conjugate fractions in Japanese patients.This study was an open-label, randomized, case-control, crossover study of colestimide 3 g/day in 40 Japanese patients

2012 Journal of diabetes and its complications

5. Bile Binding Resin

Bile Binding Resin Bile Binding Resin Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Bile Binding Resin Bile Binding Resin Aka: Bile (...) Binding Resin , Bile Acid-Binding Resin , Cholestyramine , Colestipol , Colesevelam , Welchol From Related Chapters II. Effects decreased (15-30%) increased (3-5%) s increased III. Efficacy Lowers cardiovascular mortality by 30% Reduces risk IV. Adverse effects Gastrointestinal Effects Reduce Adverse GI side effects Use moderate doses: 8-10 g per day Increase or supplement with Colesevelam may have less GI intolerance Interferes with fat soluble bsorption Take 2 hours before or 4 hours after Resin

2015 FP Notebook

6. Drug-Resin Drug Interactions in Patients with Delayed Gastric Emptying: What is optimal time window for drug administration? (PubMed)

Drug-Resin Drug Interactions in Patients with Delayed Gastric Emptying: What is optimal time window for drug administration? Most drug-drug interactions involve overlap or competition in drug metabolic pathways. However, there are medications, typically resins, whose function is to bind injurious substances such as bile acids or potassium within the digestive tract. The objective of this article is to review the functions of the stomach and the kinetics of emptying of different food forms (...) or formulations to make recommendations on timing of medication administration in order to avoid intragastric drug interactions. Based on the profiles and kinetics of emptying of liquid nutrients and homogenized solids, a window of 3 h between administration of a resin drug and another 'target' medication would be expected to allow a median of 80% of medications with particle size <1 mm to empty from the stomach and, hence, avoid potential interaction such as binding of the 'target' medication within

Full Text available with Trip Pro

2016 Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society

7. Intestinal Bile Acid Composition Modulates Prohormone Convertase 1/3 (PC1/3) Expression and Consequent GLP-1 Production in male mice. (PubMed)

Intestinal Bile Acid Composition Modulates Prohormone Convertase 1/3 (PC1/3) Expression and Consequent GLP-1 Production in male mice. Besides an established medication for hypercholesterolemia, bile acid binding resins (BABRs) present antidiabetic effects. Although the mechanisms underlying these effects are still enigmatic, glucagon-like peptide-1 (GLP-1) appears to be involved. In addition to a few reported mechanisms, we propose prohormone convertase 1/3 (PC1/3), an essential enzyme of GLP-1 (...) production, as a potent molecule in the GLP-1 release induced by BABRs. In our study, the BABR colestimide leads to a bile acid-specific G protein-coupled receptor TGR5-dependent induction of PC1/3 gene expression. Here, we focused on the alteration of intestinal bile acid composition and consequent increase of total TGR5 agonistic activity to explain the TGR5 activation. Furthermore, we demonstrate that nuclear factor of activated T cells mediates the TGR5-triggered PC1/3 gene expression. Altogether

Full Text available with Trip Pro

2016 Endocrinology

8. Effect of Bile Acid Secretion and Sequestration on GLP-1 Secretion

is a human interventional randomized controlled cross-over study including four study days for each participant. As a tool to sequester bile acids we will use sevelamer, a phosphate binding resin used in the treatment of hyperphosphataemia in adult patients with chronic kidney disease. Surprisingly, sevelamer has been shown to improve glycaemic control in patients with chronic kidney disease and type 2 diabetes. Intravenous infusion of cholecystokinin will be used to elicit gallbladder contraction (...) Effect of Bile Acid Secretion and Sequestration on GLP-1 Secretion Effect of Bile Acid Secretion and Sequestration on GLP-1 Secretion - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effect of Bile Acid

2015 Clinical Trials

9. Effect of Bile Acid Sequestration on Postprandial GLP-1 Secretion, Glucose Homeostasis and Gut Microbiota

, gut microbiota and glucose homeostasis in patients with type 2 diabetes and healthy individuals. As a tool to sequester bile acids we will use sevelamer, a phosphate binding resin used in the treatment of hyperphosphataemia in adult patients with chronic kidney disease. Surprisingly, sevelamer was recently shown to improve glycaemic control in patients with chronic kidney disease and type 2 diabetes. The investigators hypothesize that higher luminal concentrations of bile acids in the distal gut (...) Effect of Bile Acid Sequestration on Postprandial GLP-1 Secretion, Glucose Homeostasis and Gut Microbiota Effect of Bile Acid Sequestration on Postprandial GLP-1 Secretion, Glucose Homeostasis and Gut Microbiota - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2014 Clinical Trials

10. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. (PubMed)

The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Colesevelam is an anion-exchange resin with a 7-fold higher bile acid-binding capacity and fewer side effects than cholestyramine, the current first-line treatment option for cholestatic pruritus. The aim of this trial was to compare the effects of colesevelam and a placebo in patients with cholestatic pruritus. In a randomized, double-blind (...) included, and 35 were evaluable: 17 took colesevelam, 18 took the placebo, 22 were female, 8 were treatment-naive, 14 had primary biliary cirrhosis, and 14 had primary sclerosing cholangitis. The mean serum bile acid levels were comparable between the groups before treatment (P = 0.74), but they were significantly different after treatment (P = 0.01) in favor of patients treated with colesevelam. Thirty-six percent of patients in the colesevelam group reached the primary endpoint versus 35

Full Text available with Trip Pro

2010 Hepatology

11. Management of Dyslipidaemias

diabetes mellitus 29 8.1.4.4 Increased risk of haemorrhagic stroke 29 8.1.4.5 Adverse effects on kidney function 29 8.1.4.6 Interactions 29 8.2 Cholesterol absorption inhibitors 30 8.2.1 Mechanism of action 30 8.2.2 Effects on lipids 30 8.2.3 Effect on cardiovascular morbidity and mortality 30 8.2.4 Adverse effects and interactions 30 8.3 Bile acid sequestrants 30 8.3.1 Mechanism of action 30 8.3.2 Effects on lipids 30 8.3.3 Effect on cardiovascular morbidity and mortality 30 8.3.4 Adverse effects (...) Trialists CV Cardiovascular CVD Cardiovascular disease CYP Cytochrome P450 4D Die Deutsche Diabetes Dialyse Studie dal-OUTCOMES Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome DASH Dietary Approaches to Stop Hypertension DGAT-2 Diacylglycerol acyltransferase-2 DHA Docosahexaenoic acid DM Diabetes mellitus EAPC European Association of Preventive Cardiology EAS European Atherosclerosis Society EBBINGHAUS Evaluating PCSK9 Binding Antibody Influence on Cognitive Health in High

Full Text available with Trip Pro

2019 European Society of Cardiology

12. British Association of Dermatologists? guidelines for the investigation and management of generalized pruritus in adults without an underlying dermatosis

British Association of Dermatologists British Journal of Dermatology (2018) 178, pp34–60 BAD guidelines for generalized pruritus, 2018, G.W.M. Millington et al. 41For pruritus associated with parenchymal liver disease, cholestyramine is often given as ?rst-line therapy, although there is limited evidence. Cholestyramine, colestipol and cole- sevelam (anion exchange binding resins) bind bile salts in the gut lumen, thus preventing absorption of bile acids in the ter- minal ileum. 144,145 A meta (...) patients with chronic GPWOR. Note that ferritin is an acute-phase pro- teinandmaybeelevatedinasituationofironde?ciency. Where iron de?ciency is suspected, and ferritin is appar- ently ‘normal’, it may be necessary to check serum iron and total iron binding capacity as well. A trial of iron replacement should be given if the ferritin is below the lower limit of the reference range (between 15 and 25 lgL 1 in most U.K. lab- oratories) or if there is anaemia or microcytosis not attributa- ble to any other

2018 British Association of Dermatologists

13. Prevention and Management of Cardiovascular Disease Risk in Primary Care

, starting and keeping the patient on a statin is most important. Peer Simplified Guideline: Prevention & Management of CVD Risk in Primary Care | Feb 2015 Clinical Practice Guideline Page 10 of 18 Background NON-STATINS Non-statins include fibrates, niacin, ezetimibe, and bile acid binding resins. There is evidence that fibrates alone reduce non-fatal myocardial infarction but considerably less overall CVD reduction than statins and no mortality benefit. 5 Added to statins, fibrates have no benefit. 5 (...) One old trial involving niacin suggested some benefit but studies following the introduction of statins have failed to show a benefit with niacin added to a statin. 5 Fibrates, niacin, and bile acid resins generally have a higher incidence of adverse effects compared to statins. 5 Ezetimibe is well tolerated but has no demonstrated effect on mortality or CVD in primary prevention. 5 The IMPROVE-IT trial, in which ezetimibe 10mg was added to simvastatin 40mg compared to simvastatin 40mg alone

2016 Toward Optimized Practice

15. Screening and Management of Lipids

of myopathy and rhabdomyolysis. Bile acid resins. Cholestyramine, colestipol, and colesevelam are generally considered second line because of poor patient tolerability to side effects and difficult dosing/administration time. These drugs have been shown to reduce LDL-C cholesterol 15-30%, depending on dose. They are available in powder and tablet form. Resins work by binding cholesterol in the gut and interfering with absorption. They may increase triglycerides and should not be initiated in individuals (...) . Pharmacologic Treatment: Statins Statins the first-line agents. Statins are the first-line agents for lipid management. Statins have the advantage of potency, tolerability, safety, and strong clinical trial data supporting benefit. Bile acid resins are generally more expensive per LDL-C reduction, and have much higher rates of side effects. Fibrates are well tolerated, but have minimal impact on LDL-C and have not shown dramatic results in terms of event reduction. Niacin is effective at improving metabolic

2016 University of Michigan Health System

16. Vyndaqel (tafamidis meglumine)

(T 4 ) and the retinol-retinol binding protein complex in the body (Ando Y , et al. Rare/Intractable Disease Project supported by the Health and Labour Sciences Research Grant: Amyloidosis Research Committee, 2010 Clinical Practice Guideline for Amyloidosis. 2010;20-26). The typical age of onset is the 30s to 60s. Sensory, motor, and autonomic neuropathy progresses from distal to proximal and death comes on average 3 to 15 years following symptom onset. In addition to wild-type TTR having (...) to 1.1 per 1 million population (the Japanese population of patients is estimated at approximately 111-140) (Motozaki Y, et al. Journal of Clinical and Experimental Medicine. 2009;229:357-362, Kato-Motozaki Y, et al. J Neurol Sci. 2008;270:133-140). The active substance Tafamidis Meglumine (tafamidis) is a benzoxazole derivative developed at FoldRx Pharmaceuticals (the US) (currently, Pfizer Inc.). It is a drug that binds to tetrameric TTR in plasma and inhibits dissociation into monomers, thereby

2013 Pharmaceuticals and Medical Devices Agency, Japan

17. The Agenda for Familial Hypercholesterolemia (PubMed)

impairing binding with the LDL receptor and gain-of-function mutations in proprotein convertase subtulisin/kexin type 9 [PCSK9] that enhance LDL receptor degradation). FH leads to elevated LDL concentrations, with levels in heterozygous FH generally in untreated adults >190 mg/dL LDL cholesterol (LDL-C) and in untreated children or adolescents >160 mg/dL LDL-C. Long-term exposure to elevated plasma concentrations of LDL-C begins in utero, leading in heterozygotes to premature ischemic heart disease (...) receptor is responsible for the binding and subsequent cellular uptake of apolipoprotein B (apoB)- and apoE-containing lipoproteins. The LDL receptor locus is located on chromosome 19p13.1-13.3 and comprises 18 coding regions (exons) and 17 intervening noncoding regions (introns; ). The LDL receptor gene is a housekeeping gene that is translated into LDL receptors in most tissues. The transcription is regulated by a negative feedback mechanism controlled by the cellular content of cholesterol

Full Text available with Trip Pro

2015 American Heart Association

18. Obeticholic acid (Ocaliva) - Liver Cirrhosis, Biliary

concentrations and efficacy of OCA in clinical studies and attenuate its efficacy. Therefore OCA should be taken at least 4-6 hours before or 4-6 hours after (or at as great an interval as possible) taking bile acid resin as outlined in the SmPC. No further clinically significant DDIs are expected based upon metabolic profiles of the most widely used concomitant medications in PBC patients. From a clinical point of view, the information regarding OCA´s PD, in particular on the mechanistic of the anti (...) Code): bile therapy, bile acid preparations (A05AA04) Therapeutic indication(s): OCALIVA is indicated for the treatment of primary biliary cholangitis (also known as primary biliary cirrhosis) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. Pharmaceutical form(s): Film-coated tablet Strength(s): 5 mg and 10 mg Route(s) of administration: Oral use Packaging: bottle (HDPE) Package size(s): 30 tablets

2017 European Medicines Agency - EPARs

19. Policaptil Gel Retard® in Overweight and Mild Obese Subjects

prior to the beginning of the study at a stable dosage: - pharmacological treatment for dyslipidemia [(3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (the "statins"), fibrates (gemfibrozil, clofibrate and fenofibrate), niacin/nicotinic acid, bile acid binding resins (colestipol and cholestyramine)], antidepressant such as fluoxetine and bupropion, diuretics Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your

2018 Clinical Trials

20. Guidelines for the management of dyslipidaemias

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1790 7.2 Bile acid sequestrants . . . . . . . . . . . . . . . . . . . . . .1791 7.3 Cholesterol absorption inhibitors . . . . . . . . . . . . . .1792 7.4 Nicotinic acid. . . . . . . . . . . . . . . . . . . . . . . . . . . .1792 7.5 Drug combinations . . . . . . . . . . . . . . . . . . . . . . . .1792 7.5.1 Statins and bile acid sequestrants . . . . . . . . . . . .1792 7.5.2 Statins and cholesterol absorption inhibitors . . . . .1792 7.5.3 Other combinations (...) . Practical approach to reach low-density lipoprotein-cholesterol goal Addendum III. Inhibitors and inducers of enzymatic pathways involved in statin metabolism Addendum IV. Additional references ESC/EAS Guidelines 1770Abbreviations and acronyms 4D Die Deutsche Diabetes Dialyse Studie 4S Scandinavian Simvastatin Survival Study ABC-1 ATP-binding cassette transporter 1 ACCORD Action to Control Cardiovascular Risk in Diabetes ACS acute coronary syndrome AIM-HIGH Atherothrombosis Intervention in Metabolic

2011 European Society of Cardiology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>